Overview of Chemotherapy-Induced Diarrhea

Seminars in Oncology Nursing

Volumn 19, Issue SUPPL. 3, 2003, Pages 2-5

  Viele, Carol S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; LAXATIVE; OXALIPLATIN; PRODRUG; TEGAFUR; TOPOTECAN; UFT; CAMPTOTHECIN; DRUG DERIVATIVE; OCTREOTIDE;

CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; DIARRHEA; DIET THERAPY; DOCTOR PATIENT RELATION; DRUG DOSE REGIMEN; HERB; HUMAN; LABORATORY TEST; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; PATIENT CARE; PHYSICAL EXAMINATION; REVIEW; TEA; TREATMENT OUTCOME; VOMITING; CHEMICALLY INDUCED DISORDER; NEOPLASM; NURSE PATIENT RELATIONSHIP; NURSING; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; ONCOLOGY NURSING; QUALITY OF LIFE; STANDARD;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DIARRHEA; FLUOROURACIL; HUMANS; NEOPLASMS; NURSE-PATIENT RELATIONS; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; OCTREOTIDE; ONCOLOGIC NURSING; QUALITY OF LIFE;

EID: 85047693931     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.soncn.2003.09.007     Document Type: Article

References (16)

1. National Cancer Institute (NCI): Common Terminology Criteria for Adverse Effects (CTCAE) v. 3.0. Available at: http://ctep.cancer.gov/reporting/ctc.html (accessed September 3, 2003)
2. Ippoliti C: Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm 55:1573-158, 1998
3. Rutledge DN, Engelking C: Cancer-related diarrhea: Selected findings of a national survey of oncology nurse experiences. Oncol Nurs Forum 25:861-873, 1998
4. Hogan CM: The nurse's role in diarrhea management. Oncol Nurs Forum 25:879-886, 1998
5. Engelking C, Rutledge DN, Ippoliti C, et al: Cancer-related diarrhea: A neglected cause of cancer-related symptom distress. Oncol Nurs Forum 25:859-860, 1998
6. Cassidy J, Misset JL: Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29:11-20, 2002
7. Malet-Martino M, Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 7:288-323, 2002
8. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxaliplatin + CPT-11 in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
9. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC ). Proc Am Soc Clin Oncol 21:129a, 2002 (abstr 512)
10. de Gramont A, Boni C, Navarro M, et al: Oxaliplatin/5-FU/LV in adjuvant colon cancer: Safety results of the international randomized MOSAIC trial. Proc Am Soc Clin Oncol 21:132a, 2002 (abstr 525)
11. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
12. Saltz L, Cox J, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
13. de Bono JS, Rowinsky EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br Med Bull 64:227-254, 2002
14. Armandola E: ESMO/ASCO Joint Symposium-Whereto with targeted treatments? Available at: www.medscape.com/viewprogram/2108_pnt (accessed August 8, 2003)
15. Arbuckle RB, Huber SL, Zacker C: The consequences of diarrhea occurring during chemotherapy for colorectal cancer: A retrospective study. Oncologist 5:250-259, 2000
16. Cope DG: Management of chemotherapy-induced diarrhea and constipation. Nurs Clin North Am 36:695-707, 2001